The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies
M Mehrpouri - European Journal of Pharmacology, 2022 - Elsevier
Abstract CXC motif chemokine 12 (CXCL12), also known as stromal cell-derived factor-1
(SDF-1), is produced by the bone marrow microenvironment. This chemokine binds and …
(SDF-1), is produced by the bone marrow microenvironment. This chemokine binds and …
[HTML][HTML] The anti-leukemic activity of natural compounds
The use of biologically active compounds has become a realistic option for the treatment of
malignant tumors due to their cost-effectiveness and safety. In this review, we aimed to …
malignant tumors due to their cost-effectiveness and safety. In this review, we aimed to …
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 …
KJ Aichberger, M Mayerhofer, MT Krauth, H Skvara… - Blood, 2005 - ashpublications.org
Antiapoptotic members of the bcl-2 family have recently been implicated in the pathogenesis
of chronic myeloid leukemia (CML), a hematopoietic neoplasm associated with the …
of chronic myeloid leukemia (CML), a hematopoietic neoplasm associated with the …
[HTML][HTML] Caffeic acid enhances the anti-leukemic effect of imatinib on chronic myeloid leukemia cells and triggers apoptosis in cells sensitive and resistant to imatinib
G Feriotto, F Tagliati, R Giriolo, F Casciano… - International Journal of …, 2021 - mdpi.com
Among the phenolic acids tested on the K562 cell line, a model of chronic myeloid leukemia
(CML), caffeic acid (CA) was biologically active on sensitive and imatinib (IM)-resistant cells …
(CML), caffeic acid (CA) was biologically active on sensitive and imatinib (IM)-resistant cells …
Pharmacogenetics and pharmacogenomics of targeted therapeutics in chronic myeloid leukemia
The advent of targeted therapeutics has greatly improved outcomes of chronic myeloid
leukemia (CML) patients. Despite increased efficacy and better clinical responses over …
leukemia (CML) patients. Despite increased efficacy and better clinical responses over …
The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells
KJ Aichberger, M Mayerhofer, A Vales, MT Krauth… - Blood, 2006 - ashpublications.org
Basophil numbers are typically elevated in chronic myeloid leukemia (CML) and increase
during disease progression. Histamine is an essential mediator and marker of basophils and …
during disease progression. Histamine is an essential mediator and marker of basophils and …
FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment
M Nakajo, S Jinnouchi, H Inoue, M Otsuka… - Clinical nuclear …, 2007 - journals.lww.com
We report 2 patients with chronic myeloid leukemia in the chronic phase showing diffusely
increased F-18 fluorodeoxyglucose (FDG) uptake in the bone marrow before treatment …
increased F-18 fluorodeoxyglucose (FDG) uptake in the bone marrow before treatment …
[PDF][PDF] Vascular endothelial growth factor receptor 2 (VEGFR2) gene polymorphism and treatment outcome following imatinib therapy in Iraqi patients with chronic …
Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative disorder derived by
formation of Philadelphia chromosome (Ph chromosome). Formation of the Ph chromosome …
formation of Philadelphia chromosome (Ph chromosome). Formation of the Ph chromosome …
[HTML][HTML] Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
M Serpa, SS Sanabani, PE Dorliac-Llacer, M Conchon… - BMC Hematology, 2010 - Springer
Background The monitoring of BCR-ABL transcript levels by real-time quantitative
polymerase chain reaction (RT-qPCR) has become important to assess minimal residual …
polymerase chain reaction (RT-qPCR) has become important to assess minimal residual …
In vivo effects of imatinib mesylate on human haematopoietic progenitor cells
H Agis, E Jaeger, B Doninger, C Sillaber… - European journal of …, 2006 - Wiley Online Library
Background Imatinib mesylate has considerable antineoplastic activity in patients with
chronic myeloid leukaemia (CML) and some solid tumours. Although originally regarded as …
chronic myeloid leukaemia (CML) and some solid tumours. Although originally regarded as …